Cardiovascular disease (CVD) is among the most prevalent of all diseases and leading causes of death in the world. Approximately 17.5 million people die each year from cardiovascular diseases, an estimated 31% of all deaths worldwide and this is expected to grow to more than 23.6 million by 2030.
Global Markets Direct’s, ‘Thromboembolism - Pipeline Review, H1 2019’, provides an overview of the Thromboembolism pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Thromboembolis...
Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H2 2018’, provides an overview of the Critical Limb Ischemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for ...
Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H2 2018’, provides an overview of the Atherosclerosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Atherosclerosi...
Global Markets Direct’s, ‘Stroke - Pipeline Review, H2 2018’, provides an overview of the Stroke pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis b...
Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.
The report provides comprehensive information on the...
Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H2 2018’, provides an overview of the Arrhythmias pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete ...
Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H2 2018’, provides an overview of the Myocardial Infarction pipeline landscape.
The report provides comprehensive information on the therapeutics under development for My...
Global Markets Direct’s, ‘Atrial Fibrillation - Pipeline Review, H2 2018’, provides an overview of the Atrial Fibrillation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Atrial...
Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H2 2018’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.
The report provides comprehensive information on the therapeutics unde...
Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H2 2018’, provides an overview of the Pulmonary Embolism pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pulmonar...
Global Markets Direct’s, ‘Restenosis - Pipeline Review, H2 2018’, provides an overview of the Restenosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Restenosis, complete wit...
Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.
The report provides comprehensive information on the therapeutics under developm...
Global Markets Direct’s, ‘Myocarditis - Pipeline Review, H2 2018’, provides an overview of the Myocarditis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Myocarditis, complete ...
Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2018’, provides an overview of the Hypertension pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hypertension, comple...
Global Markets Direct’s, ‘Myocardial Fibrosis - Pipeline Review, H1 2018’, provides an overview of the Myocardial Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Myocar...